Novaptech
Private Company
Total funding raised: $1.8M
Overview
Novaptech is a private, revenue-generating biotechnology CRO and platform company focused on aptamer development. Spun out from an academic lab with over 30 years of aptamer expertise, the company offers end-to-end custom aptamer services and is developing its own pipeline of aptamer-based diagnostic kits and biosensors. With a global client base and a focus on replacing antibodies in various applications, Novaptech positions itself at the forefront of synthetic ligand technology for quantitative detection and point-of-care testing.
Technology Platform
Proprietary SELEX process for aptamer selection, optimization, and characterization, integrated into the development of aptamer-based fluorimetric/colorimetric biosensors (aptasensors) for quantitative detection.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Novaptech competes in the niche aptamer CRO space against other specialized firms, while its aspirational product business would face competition from established diagnostic and biosensor companies using antibody or other technologies. Its key differentiator is its deep, founder-led scientific expertise in aptamer selection and optimization.